The propensity of systemic beta-adrenergic blockers to cause bronchoconstriction in
patients with reactive airway disease is well recognized. A study was carried out to …

To evaluate the effects of two beta-adrenergic blocking agents on cardiopulmonary function,
we investigated two topical ophthalmologic preparations, betaxolol 1% and timolol 0.5%, in …

We evaluated the use of topically administered betaxolol, a cardioselective beta-adrenergic
blocking agent, in 11 patients (eight women and three men, 40 to 81 years old) who had …

Timolol, a β-adrenergic blocking agent, recently became available for the treatment of
glaucoma. We report the occurrence of acute bronchospasm in a previously asymptomatic …

A patient with glaucoma simplex and chronic pulmonary obstruction was treated with the
non‐selective β‐adrenergic blocking agent timolol in ophthalmic solution of 0.25% for 1 1/2 …

1. The inadvertent administration of timolol to asthmatic patients continues to cause
occasional severe and even fatal attacks of asthma. The (R)‐enantiomer of timolol, L …

We evaluated the use of topically administered betaxolol 0.5% in 101 glaucoma patients (47
men and 54 women) who had chronic obstructive pulmonary disease, asthma, or timolol …

B antagonists eye drops are most effective for the treatment of chronic open angle
glaucoma. By this way of administration they have a very good systemic bioavailability …

The extent of impairment of respiratory function in a group of 52 elderly, glaucomatous
patients receiving topical timolol therapy was investigated. To predict those patients who …

Fifty-two elderly glaucomatous patients, without a history of asthma or obstructive airways
disease, who were using topical timolol for control of intraocular pressure were recruited …